MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Daunorubicin hydrochloride

CAS No. : 23541-50-6

MCE 站：Daunorubicin hydrochloride

产品活性：Daunorubicin (Daunomycin) hydrochloride 是具有有效抗肿瘤活性的 DNA 拓扑异构酶 II (topoisomerase II)。Daunorubicin 抑制敏感和耐药的埃利氏腹水肿瘤细胞的 DNA 和 RNA 合成。

研究领域：Cell Cycle/DNA Damage  |  Antibody-drug Conjugate/ADC Related  |  Anti-infection  |  Autophagy  |  Apoptosis

作用靶点：Topoisomerase  |  DNA/RNA Synthesis  |  ADC Cytotoxin  |  Bacterial  |  Autophagy  |  Apoptosis  |  Antibiotic

In Vitro: The mean IC₅₀ value is 0.04 μM for Daunorubicin (RP 13057) hydrochloride in Molt-4 cells. Daunorubicin (RP 13057) hydrochloride belongs to the anthracyclines, a group of cytotoxic chemotherapeutics. The cytotoxic effects of anthracyclines are caused by DNA intercalation and the ability to interfere with DNA transcription and replication by inhibiting Topoisomerase II as well as by producing reactive oxygen species.
Daunorubicin (RP 13057) hydrochloride inhibits of both DNA and RNA synthesis in HeLa cells over a concentration range of 0.2 through 2 μM. The IC₅₀ value is 0.4 μM for Daunorubicin (RP 13057) hydrochloride in human pancreatic cell line L3.6.

In Vivo: Urinary protein excretion, serum creatinine, and blood urea nitrogen (BUN) level are significantly increased in group Daunorubicin (RP 13057) hydrochloride (3 mg/kg, i.v.) compared with those in group Control. Administration of Daunorubicin (DNR) causes a significant increase in malondialdehyde (MDA) level in renal tissue compared with that in the control group.

相关产品：Natural Product Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Natural Product Library  |  FDA-Approved Drug Library  |  Toxins for Antibody-Drug Conjugate Research Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Antibacterial Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  FDA Approved & Pharmacopeial Drug Library  |  Antibiotics Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Blood Cancer Compound Library  |  MG-132  |  Rapamycin  |  LY294002  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Puromycin dihydrochloride  |  Paclitaxel  |  Cycloheximide  |  Y-27632 dihydrochloride  |  Chloroquine  |  Acetylcysteine  |  Angiotensin II human  |  SP600125  |  5-Fluorouracil  |  Staurosporine  |  Dexamethasone  |  Bortezomib  |  Tamoxifen  |  2-Deoxy-D-glucose  |  Oxaliplatin  |  Gemcitabine  |  Verteporfin  |  Doxycycline (hyclate)  |  Decitabine  |  Actinomycin D  |  Temozolomide  |  Cyclosporin A  |  G-418 disulfate

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。